Join
Live feed
·
PRReleasevia Quantisnow
Aardvark Therapeutics Inc. logo

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
AARD· Aardvark Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AARD (Aardvark Therapeutics Inc.) and more on Quantisnow.